Neuropsychiatric Disease and Treatment · 2014 · 54 citations · 26 references
MedicineNutritional SciencesPharmacologyDementiaHuman NutritionNutrition In Older AdultsCognitive AssessmentCognitive DisordersCognitive Function AssessmentCognitive HealthCognitive ImpairmentDementia TreatmentCognitive EffectsCognitive Impairment EvaluationDietary Supplement EfficacyDietary Supplementation EffectsMental State ExaminationMild Cognitive Impairment TherapyNutrient-cognition RelationshipsNutritional Interventions For Dementia
A prospective cohort, noncomparative, multicenter trial was conducted to explore the potential of a phytotherapeutic compound, available as a dietary supplement and containing extracts of Bacopa monnieri and Haematococcus pluvialis (astaxanthin) plus phosphatidylserine and vitamin E, in improving cognition in subjects diagnosed with mild cognitive impairment. Enrolled subjects (n=104) were aged 71.2±9.9 years and had a mini-mental state examination score of 26.0±2.0 (mean ± standard deviation). They underwent the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) test and the clock drawing test at baseline and upon completion of a 60-day period of dietary supplementation with one tablet daily of the tested compound. In 102 assessable subjects, total ADAS-cog scores improved from 13.7±5.8 at baseline to 9.7±4.9 on day 60, and the clock drawing test scores improved from 8.5±2.3 to 9.1±1.9. Both changes were statistically significant (P<0.001). Memory tasks were the individual components of ADAS-cog showing the largest improvements. In a multivariate analysis, larger improvements in total ADAS-cog score were associated with less compromised baseline mini-mental state examination scores. Perceived efficacy was rated as excellent or good by 62% of study subjects. The tested compound was well tolerated; one nonserious adverse event was reported in the overall study population, and perceived tolerability was rated excellent or good by 99% of the subjects. In conclusion, dietary supplementation with the tested compound shows potential for counteracting cognitive impairment in subjects with mild cognitive impairment and warrants further investigation in adequately controlled, longer-term studies.
26
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Ronald C. Petersen, Glenn E. Smith, Stephen C. Waring et al. · Archives of Neurology · 1999 · 9K citations
Medicine, Neurology, Psychiatry +17
A new rating scale for Alzheimer's disease
Wilma G. Rosen, Richard C. Mohs, Kenneth L. Davis · American Journal of Psychiatry · 1984 · 4.2K citations
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Ronald Petersen, Ronald G. Thomas, Michael Grundman et al. · New England Journal of Medicine · 2005 · 1.9K citations · Full text